Does stimulation of salivary glands by oral intake increase uptake and toxicity of PSMA-ligands?

Completed

• Conditions: dry mouth; xerostomia; 10036958

• Registration Number: NL-OMON49260
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

- Received PSMA PET/CT on clinical indication (< 1 month before study scan)
- Salivary glands and lacrimal glands visible in the baseline PSMA PET/CT scan

Exclusion Criteria

- Poor quality of the baseline PSMA PET/CT scan
- Planned start or changes in treatment between the baseline scan and study
scan.
- Age <18y
- Inability to provide informed consent
- Diabetes Mellitus
- Vegan diet
- Claustrophobia
- History of disease or treatment involving the salivary glands, like malignant
or benign tumour, sialoadenitis, stone, surgery, SLE, RT to head-neck, etc

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The accumulation of systemically administered PSMA-ligands in salivary glands<br /><br>on PET/CT.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To screen for potential influence of oral intake on the biodistribution of<br /><br>PSMA-ligands on PET/CT in other organs and tumour.</p><br>